Allogene Therapeutics Inc. (NASDAQ:ALLO), Stock Drops -61.51% Far This Year; What Analysts Say Next? – Marketing Sentinel
Home  »  Technologies   »  Allogene Therapeutics Inc. (NASDAQ:ALLO), Stock Dr...

Allogene Therapeutics Inc. (NASDAQ:ALLO), Stock Drops -61.51% Far This Year; What Analysts Say Next?

In last trading session, Allogene Therapeutics Inc. (NASDAQ:ALLO) saw 1.54 million shares changing hands with its beta currently measuring 0. Company’s recent per share price level of $11.96 trading at -$0.37 or -3.00% at ring of the bell on the day assigns it a market valuation of $1.72B. That closing price of ALLO’s stock is at a discount of -227.09% from its 52-week high price of $39.12 and is indicating a premium of 3.51% from its 52-week low price of $11.54. Taking a look at company’s average trading volume of 1.71 million if we extend that period to 3-months.

Allogene Therapeutics Inc. (NASDAQ:ALLO) trade information

Upright in the red during last session for losing -3.00%, in the last five days ALLO remained trading in the red while hitting it’s week-highest on Friday, 01/07/22 when the stock touched $11.96 price level, adding 14.69% to its value on the day. Allogene Therapeutics Inc.’s shares saw a change of -19.84% in year-to-date performance and have moved -12.12% in past 5-day. Allogene Therapeutics Inc. (NASDAQ:ALLO) showed a performance of -16.36% in past 30-days.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


Allogene Therapeutics Inc. (ALLO) estimates and forecasts

Statistics highlight that Allogene Therapeutics Inc. is scoring comparatively lower than the scores of other players of the relevant industry. The company lost -47.15% of value to its shares in past 6 months, showing an annual growth rate of 4.81% while that of industry is 7.90. Apart from that, the company came raising its revenue forecast for fiscal year 2022. The company is estimating its revenue growth to decrease by -11.30% in the current quarter and calculating -148.00% decrease in the next quarter.

16 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of -$10k for the same.

In 2022, company’s earnings growth rate is likely to be around -13.80% while estimates for its earnings growth in next 5 years are of 1.00%.

ALLO Dividends

Allogene Therapeutics Inc. is more likely to be releasing its next quarterly report between February 23 and February 28 and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.

Allogene Therapeutics Inc. (NASDAQ:ALLO)’s Major holders

Insiders are in possession of 34.64% of company’s total shares while institution are holding 62.92 percent of that, with stock having share float percentage of 96.27%. Investors also watch the number of corporate investors in a company very closely, which is 62.92% institutions for Allogene Therapeutics Inc. that are currently holding shares of the company. Tpg Group Holdings (sbs) Advisors, Inc. is the top institutional holder at ALLO for having 18.72 million shares of worth $481.01 million. And as of Sep 29, 2021, it was holding 13.13% of the company’s outstanding shares.

The second largest institutional holder is Blackrock Inc., which was holding about 7.27 million shares on Sep 29, 2021. The number of shares represents firm’s hold over 5.10% of outstanding shares, having a total worth of $186.87 million.

>> 7 Top Picks for the Post-Pandemic Economy <<

On the other hand, Growth Fund Of America Inc and Smallcap World Fund are the top two Mutual Funds which own company’s shares. As of Sep 29, 2021, the former fund manager was holding 7.29 million shares of worth $187.41 million or 5.12% of the total outstanding shares. The later fund manager was in possession of 2.5 million shares on Sep 29, 2021, making its stake of worth around $64.29 million in the company or a holder of 1.76% of company’s stock.

Leave a Comment

Your email address will not be published. Required fields are marked *

On Key

Related Posts



Download Free eBook For



100% free. stop anytime no spam